Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the web page.
    Difference
    0.1%
    Check dated 2024-06-13T22:23:02.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the rate of complete response to the combination treatment of ibrutinib, fludarabine, and pembrolizumab for high-risk or relapsed/refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:12.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the inclusion and exclusion criteria for participants, such as health conditions and prior treatments. This change provides more comprehensive information for potential participants and researchers about who can join the study.
    Difference
    36%
    Check dated 2024-05-22T20:32:57.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:39:31.000Z thumbnail image

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.